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        Nucleophosmin (NPM; also known as B23, NO38, or numatrin) 
is a nucleolar protein that shuttles continuously between the nu-
cleus and the cytoplasm (for review see   Grisendi et al., 2006  ). 
Because of its nucleolar localization, intrinsic RNase activity, 
and association with maturing preribosomal ribonucleoproteins, 
NPM has been proposed to regulate ribosomal RNA transcrip-
tion/processing and the transport of preribosomal particles to 
the cytoplasm (  Grisendi et al., 2006  ). One major feature of 
NPM is to display molecular chaperone activity: it functions as 
a histone chaperone, favoring DNA-histone and nucleosome as-
sembly in vitro, and also interacts with a wide range of unfolded 
proteins, inducing proper folding in the active state (  Grisendi 
et al., 2006  ). In vivo, NPM interacts with many growth regulators, 
including the tumor suppressors p53 and ARF, and the HDM2 
(Mdm2 in mouse) oncogene. Not surprisingly, this translates into 
pleiotropic biological effects, including regulation of nuclear 
export, DNA transcription, DNA repair, and cell proliferation and 
survival (  Grisendi et al., 2006  ). 
  Much of the interest in NPM derives from its involvement 
in cancer. NPM is frequently overexpressed in carcinomas and 
is involved in chromosome translocations in hematological ma-
Nucleophosmin (NPM) is frequently mutated in acute 
  myeloid leukemias and is thought to act as both a proto-
oncogene and a tumor suppressor. Although genetic and 
molecular evidence has shed light on the mechanisms of 
NPM-mediated tumor suppression, the potential role of 
NPM mutants as oncogenes remains ill deﬁ  ned.  Now, 
new data provide a straightforward mechanism for this 
latter function, as NPM is shown to regulate the stability 
and the function of MYC. Remarkably, the same leitmotif 
of   “  placing a critical cell regulator in the wrong place at 
the wrong time  ”   appears to underscore all the cancer-
promoting activities of mutated NPM.
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lignancies, where it forms fusion proteins with different partners 
(for review see   Grisendi et al., 2006  ). Remarkably, heterozygous 
mutations of NPM are found in     35% of acute myeloid leuke-
mias (AMLs), which makes NPM the most frequently mutated 
gene in AML (  Falini et al., 2005  ). Despite their genetic hetero-
geneity (  >  20 mutations have been described), all AML muta-
tions of NPM introduce a de novo nuclear export signal, which 
is responsible for the cytoplasmic accumulation of the mutated 
protein (  Mariano et al., 2006  ). 
  The nature of the cancer alterations (overexpression and 
heterozygous mutations) initially led to NPM being proposed as 
a proto-oncogene. Mouse genetics experiments highlighted a 
different picture. Although inactivation of NPM in the germ line 
leads to embryonic lethality, studies in cultured NPM-null cells 
or mice carrying a single inactivated NPM allele provided evi-
dence for a tumor-suppressor role. In particular, it was shown 
that: (1) NPM-null cells accumulate DNA damage (  Colombo 
et al., 2005  ) and have increased centrosome numbers (  Grisendi 
et al., 2005  ), which suggests genomic instability; and (2) hetero-
zygous animals develop signs of myelodysplastic syndrome and 
display accelerated lymphomagenesis when crossed with    -myc 
transgenic mice (  Grisendi et al., 2005  ). 
  At the molecular level, the tumor suppressor activity of 
NPM seems to impinge directly and indirectly on the regula-
tion of p53 (for review see   Grisendi et al., 2006  ). One well-
characterized mechanism involves the ARF tumor suppressor. 
In NPM-null cells, ARF loses its physiological localization in the 
nucleolus and becomes unstable, which suggests that NPM is 
critical for the proper localization and stability of ARF (  Colombo 
et al., 2005  ). Notably, this function of NPM is lost for AML-
  associated NPM alleles (NPM-mut), which compete with wild-
type NPM for ARF binding but target ARF to the cytoplasm, 
where it becomes more susceptible to degradation. This, in turn, 
leads to impaired ARF-dependent activation of p53 (  Fig. 1  ; 
    Colombo et al., 2006  ). 
  Does this settle the issue? Probably not, as one observa-
tion remains unexplained. AMLs carrying mutated NPM alleles 
display, by and large (    85% of the cases), a normal karyotype, 
and show no apparent signs of genomic instability. How can this 
be reconciled with the fact that malignancies carrying in-
activation of the ARF  –  p53 pathway are usually associated with 
genome instability and multiple cytogenetic abnormalities? 
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stabilized. NPM-mut maintains the property of interacting with 
FBW7     but delocalizes it to the cytoplasm, where it is de-
graded, thus leading to accumulation of MYC and increased 
MYC signaling (  Fig. 1  ). Thus, mutations of NPM seem to si-
multaneously dampen a tumor-suppressor pathway (p53  –  ARF) 
and enhance an oncogenic one (MYC;   Fig. 1  ). Alterations of 
NPM alone would therefore be suffi  cient to cause leukemia. To 
prove this point, one would need to show that the concomitant 
inactivation of ARF and activation of MYC are indeed neces-
sary for the leukemogenic activity of NPM-mut, an issue that is 
still outstanding. 
  One remarkable feature of the system is that the mecha-
nisms underlying the dual function of NPM-mut seem to adhere 
to the same molecular blueprint, i.e., that of   “  placing a critical 
cell regulator in the wrong place at the wrong time.  ”   In the case 
of both ARF and FBW7     (which, incidentally, is frequently 
mutated/deleted in human cancers and is a haploinsuffi  cient 
tumor suppressor in mice;   Minella and Clurman, 2005  ), the 
mislocalization of the proteins to the nucleoplasm or to the 
cytoplasm in NPM-null or NPM-mut  –  expressing cells, respec-
tively, causes their inappropriate degradation. This provides 
fodder for new questions and further speculation. For instance, 
the degradation of ARF is, at least in part, ubiquitin independent 
and mediated by a noncanonical proteosomal pathway (the REG    
proteasome;  Chen et al., 2007 ). Is a similar mechanism operational 
In the general scheme of cancerogenesis, genomic instability 
is thought to represent the enabling condition that induces 
the emergence of additional genetic alterations needed to  confer 
the selectable proliferative advantage to tumor cells. Of course, 
it cannot be excluded that as-yet-undetected point mutations 
(other than those affecting NPM) or minimal cytogenetic altera-
tions are present in NPM-mutated AMLs. There is, however, 
one alternative possibility, i.e., that NPM-mut impinges both on 
tumor suppressor and oncogenic circuitries. Under this scenario, 
a mutant NPM allele might confer the quasi-entire repertoire 
of alterations needed for transformation, and there would be no 
selective pressure on leukemic clones displaying genomic insta-
bility (which might still be present but would simply be diluted 
within the total leukemic population). 
  In this issue, Bonetti et al. (see p. 19) describe one 
mechanism through which mutations of NPM might activate 
oncogenic pathways. They show that, in the absence of NPM 
or in the presence of NPM-mut, cells express increased levels 
of the MYC proto-oncogene. The critical player in this circuitry 
is FBW7    , a nucleolar ubiquitin ligase previously implicated 
in the ubiquitination/degradation of MYC (  Yada et al., 2004  ). 
The authors demonstrate that NPM interacts with FBW7     and 
that, in the absence of NPM, FBW7     loses its nucleolar local-
ization and is rapidly degraded by the proteasome. As a conse-
quence, ubiquitination of MYC is defective and the protein is 
  Figure 1.       Mutated NMP attenuates an oncosuppressor pathway and enhances an oncogenic one.   Normal cell: NPM is mainly localized in the nucleolus 
and is required for nucleolar accumulation and stability of FBW7     and ARF. This is relevant for the control of MYC turnover and provides an active pool of 
ARF ready to inactivate the HDM2-mediated p53 degradation in response to cellular stress. AML blast: NPM-mut is mainly localized to the cytoplasm and 
causes cytoplasmic delocalization and degradation of ARF and FBW7    . As a consequence, HDM2 can induce ubiquitination/degradation of p53, and 
MYC accumulates and activates its target genes.     9 NUCLEOPHOSMIN AND LEUKEMIA   • Di Fiore 
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for FBW7     as  well?  Moreover,  the   “ physiological ”   function  of 
NPM appears to be linked to ensuring the proper intracellular 
localization of ARF and FBW7     (and possibly of other pro-
teins). Is NPM a passive   “  reservoir  ”   for these proteins? This 
seems unlikely, as NPM shuttles continuously between the nu-
cleolus, the nucleoplasm, and the cytoplasm; this dynamic be-
havior is more readily compatible with some form of regulation 
of the traffi  cking of its interactors. In the case of the p53  –  ARF 
pathway, the hypothesis has been put forward that NPM might 
be a nucleolar sensor of oncogenic stress (  Fig. 1  ). Under normal 
conditions, NPM sequesters ARF in the nucleolus. By sensing 
oncogene activation, or indeed, in other, more physiological 
conditions, NPM might traffi  c ARF to the nucleoplasm for acti-
vation of p53. Is this what is actually happening? And if so, how 
is it regulated? Are similar regulatory mechanisms involved in 
the NPM/FBW7     circuitry? All these issues deserve further ex-
perimental attention. 
  Finally, it should be noted that FBW7     is part of an SCF 
ubiquitination complex that targets other growth-promoting 
proteins, such as cyclin E and NOTCH, for degradation. 
Bonetti et al. (  2008  ) did not investigate whether NPM and its 
mutants also regulate these proteins through the FBW7     con-
nection. This is an interesting issue, as both MYC and NOTCH 
regulate the self renewal of stem cells, and FBW7     has  been 
implicated in the control of stem cell quiescence (  Thompson 
et al., 2008  ). These observations, together with those reported 
by Bonetti et al. (  2008  ), lead us to question whether NPM is 
involved in the regulation of stem cell functions, an activity 
that could be critical for the selection of NPM mutations dur-
ing leukemogenesis. 
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